Now where do we STAND with crizanlizumab?

Affiliations

¹ Sickle Cell Branch, The National Heart, Lung, and Blood Institute, Bethesda, 20892 MD, USA.
² Sickle Cell Branch, The National Heart, Lung, and Blood Institute, Bethesda, 20892 MD, USA. Electronic address: sweelay.thein@nih.gov.

Sebastian Mendez-Marti et al. Lancet Haematol. 2025 Apr.

. 2025 Apr;12(4):e232-e233.

doi: 10.1016/S2352-3026(25)00033-X. Epub 2025 Mar 12.

¹ Sickle Cell Branch, The National Heart, Lung, and Blood Institute, Bethesda, 20892 MD, USA.
² Sickle Cell Branch, The National Heart, Lung, and Blood Institute, Bethesda, 20892 MD, USA. Electronic address: sweelay.thein@nih.gov.

No abstract available

Conflict of interest statement

We declare no competing interests.

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Abboud MR, Cançado RD, De Montalembert M, Smith WR, Rimawi H, Voskaridou E, Güvenç B, Ataga KI, Keefe D, Grosch K, Watson J, Reshetnyak E, Nassin ML, Dei-Adomakoh Y. Abboud MR, et al. Lancet Haematol. 2025 Apr;12(4):e248-e257. doi: 10.1016/S2352-3026(24)00384-3. Epub 2025 Mar 12. Lancet Haematol. 2025. PMID: 40088922 Clinical Trial.